Journal of Applied Physiology Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

J Appl Physiol 78: 1288-1295, 1995;
8750-7587/95 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ichinose, F.
Right arrow Articles by Zapol, W. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ichinose, F.
Right arrow Articles by Zapol, W. M.

Journal of Applied Physiology, Vol 78, Issue 4 1288-1295, Copyright © 1995 by American Physiological Society

ARTICLES

Prolonged pulmonary vasodilator action of inhaled nitric oxide by Zaprinast in awake lambs

F. Ichinose, C. Adrie, W. E. Hurford and W. M. Zapol
Department of Anesthesia, Harvard Medical School, Massachusetts General Hospital, Boston 02114, USA.

Inhaled nitric oxide (NO) has been shown to selectively dilate the pulmonary vasculature. Zaprinast, an inhibitor of guanosine 3',5'-cyclic monophosphate-specific phosphodiesterase, augments smooth muscle relaxation induced by endothelium-dependent vasodilators. The present study was designed to determine whether intravenous administration of Zaprinast potentiates the vasodilating effects or prolongs the duration of action of intermittent NO inhalation. Eight awake lambs with U-46619-induced pulmonary hypertension breathed three concentrations of NO (5, 10, and 20 ppm) in a random order before and during an intravenous Zaprinast infusion (0.1 mg.kg-1.min-1). Inhaled NO decreased pulmonary arterial pressure (PAP) in a dose-dependent fashion, with mean PAP reduction at 5, 10, and 20 ppm NO inhalation of 6 +/- 1, 7 +/- 1, and 9 +/- 1 (SE) mmHg, respectively. Although the Zaprinast infusion did not change the magnitude of mean PAP reduction, it caused a statistically significant reduction of pulmonary vascular resistance and prolonged the duration of action of inhaled NO (half-times of vasodilator response to 5, 10, and 20 ppm NO inhalation: 1.9 +/- 0.1, 2.1 +/- 0.2, and 2.1 +/- 0.2 min, respectively; half-times of NO inhalation with Zaprinast: 9.7 +/- 1.7, 11.5 +/- 2.2, and 12.3 +/- 2.0, respectively). Plasma concentrations as well as the transpulmonary differences of guanosine 3',5'-cyclic monophosphate were increased by the Zaprinast infusion during NO inhalation. A stable level of pulmonary vasodilation was demonstrated in four additional lambs by combining intermittent NO breathing with an intravenous infusion of Zaprinast.


This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
K. D. Bloch, F. Ichinose, J. D. Roberts Jr., and W. M. Zapol
Inhaled NO as a therapeutic agent
Cardiovasc Res, July 15, 2007; 75(2): 339 - 348.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
O. V. Evgenov, C. J. Busch, N. V. Evgenov, R. Liu, B. Petersen, G. E. Falkowski, B. Petho, A. Vas, K. D. Bloch, W. M. Zapol, et al.
Inhibition of phosphodiesterase 1 augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs with acute pulmonary hypertension
Am J Physiol Lung Cell Mol Physiol, April 1, 2006; 290(4): L723 - L729.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
R. C. Dukarm, R. H. Steinhorn, J. A. Russell, S. Lakshminrusimha, D. Swartz, and J. J. Cummings
Selective type 5 phosphodiesterase inhibition alters pulmonary hemodynamics and lung liquid production in near-term fetal lambs
J Appl Physiol, December 1, 2005; 99(6): 2331 - 2336.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
F. L. M. Ricciardolo, P. J. Sterk, B. Gaston, and G. Folkerts
Nitric Oxide in Health and Disease of the Respiratory System
Physiol Rev, July 1, 2004; 84(3): 731 - 765.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
F. Ichinose, J. D. Roberts Jr, and W. M. Zapol
Inhaled Nitric Oxide: A Selective Pulmonary Vasodilator: Current Uses and Therapeutic Potential
Circulation, June 29, 2004; 109(25): 3106 - 3111.
[Full Text] [PDF]

Home page
 ChestHome page
H. H. Leuchte, M. Schwaiblmair, R. A. Baumgartner, C. F. Neurohr, T. Kolbe, and J. Behr
Hemodynamic Response to Sildenafil, Nitric Oxide, and Iloprost in Primary Pulmonary Hypertension
Chest, February 1, 2004; 125(2): 580 - 586.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
I. Matot and Y. Gozal
Pulmonary Responses to Selective Phosphodiesterase-5 and Phosphodiesterase-3 Inhibitors
Chest, February 1, 2004; 125(2): 644 - 651.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
L. Foubert, D. De Wolf, K. Reyntjens, Y. Van Belleghem, F. De Somer, G. Van Nooten, and E. Mortier
Intermittent Nitric Oxide Combined with Intravenous Dipyridamole in a Piglet Model of Acute Pulmonary Hypertension
Anesth. Analg., November 1, 2003; 97(5): 1497 - 1500.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
R. T. Schermuly, A. Roehl, N. Weissmann, H. A. Ghofrani, H. Leuchte, F. Grimminger, W. Seeger, and D. Walmrath
Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension
Am J Physiol Lung Cell Mol Physiol, December 1, 2001; 281(6): L1361 - L1368.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. T. SCHERMULY, E. KRUPNIK, H. TENOR, C. SCHUDT, N. WEISSMANN, F. ROSE, F. GRIMMINGER, W. SEEGER, D. WALMRATH, and H. A. GHOFRANI
Coaerosolization of Phosphodiesterase Inhibitors Markedly Enhances the Pulmonary Vasodilatory Response to Inhaled Iloprost in Experimental Pulmonary Hypertension . Maintenance of Lung Selectivity
Am. J. Respir. Crit. Care Med., November 1, 2001; 164(9): 1694 - 1700.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
H. Schutte, M. Witzenrath, K. Mayer, N. Weissmann, A. Schell, S. Rosseau, W. Seeger, and F. Grimminger
The PDE inhibitor zaprinast enhances NO-mediated protection against vascular leakage in reperfused lungs
Am J Physiol Lung Cell Mol Physiol, September 1, 2000; 279(3): L496 - L502.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. T. SCHERMULY, H. A. GHOFRANI, B. ENKE, N. WEISSMANN, F. GRIMMINGER, W. SEEGER, C. SCHUDT, and D. WALMRATH
Low-dose Systemic Phosphodiesterase Inhibitors Amplify the Pulmonary Vasodilatory Response to Inhaled Prostacyclin in Experimental Pulmonary Hypertension
Am. J. Respir. Crit. Care Med., November 1, 1999; 160(5): 1500 - 1506.
[Abstract] [Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. C. DUKARM, J. A. RUSSELL, F. C. MORIN III, B. J. PERRY, and R. H. STEINHORN
The cGMP-specific Phosphodiesterase Inhibitor E4021 Dilates the Pulmonary Circulation
Am. J. Respir. Crit. Care Med., September 1, 1999; 160(3): 858 - 865.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. Kodama and H. Adachi
Improvement of Mortality by Long-Term E4010 Treatment in Monocrotaline-Induced Pulmonary Hypertensive Rats
J. Pharmacol. Exp. Ther., August 1, 1999; 290(2): 748 - 752.
[Abstract] [Full Text]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
N. Hanasato, M. Oka, M. Muramatsu, M. Nishino, H. Adachi, and Y. Fukuchi
E-4010, a selective phosphodiesterase 5 inhibitor, attenuates hypoxic pulmonary hypertension in rats
Am J Physiol Lung Cell Mol Physiol, August 1, 1999; 277(2): L225 - L232.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
I. V. Turko, S. A. Ballard, S. H. Francis, and J. D. Corbin
Inhibition of Cyclic GMP-Binding Cyclic GMP-Specific Phosphodiesterase (Type 5) by Sildenafil and Related Compounds
Mol. Pharmacol., July 1, 1999; 56(1): 124 - 130.
[Abstract] [Full Text]

Home page
 ChestHome page
C. M. Hart
Nitric Oxide in Adult Lung Disease
Chest, May 1, 1999; 115(5): 1407 - 1417.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. W. ZIEGLER, D. D. IVY, J. W. WIGGINS, J. P. KINSELLA, W. R. CLARKE, and S. H. ABMAN
Effects of Dipyridamole and Inhaled Nitric Oxide in Pediatric Patients with Pulmonary Hypertension
Am. J. Respir. Crit. Care Med., November 1, 1998; 158(5): 1388 - 1395.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
D. D. Ivy, J. P. Kinsella, J. W. Ziegler, and S. H. Abman
Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease
J. Thorac. Cardiovasc. Surg., April 1, 1998; 115(4): 875 - 882.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. W. ZIEGLER, D. DUNBAR IVY, J. J. FOX, J. P. KINSELLA, W. R. CLARKE, and S. H. ABMAN
Dipyridamole Potentiates Pulmonary Vasodilation Induced by Acetylcholine and Nitric Oxide in the Ovine Fetus
Am. J. Respir. Crit. Care Med., April 1, 1998; 157(4): 1104 - 1110.
[Abstract] [Full Text] [PDF]

Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
S. C. Body and S. K. Shernan
The Utility of Nitric Oxide in the Postoperative Period
Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 1998; 2(1): 4 - 30.
[Abstract] [PDF]

Home page
 J. Appl. Physiol.Home page
C. Adrie, F. Ichinose, A. Holzmann, L. Keefer, W. E. Hurford, and W. M. Zapol
Pulmonary vasodilation by nitric oxide gas and prodrug aerosols in acute pulmonary hypertension
J Appl Physiol, February 1, 1998; 84(2): 435 - 441.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. R. Maclean, E. D. Johnston, K. M. Mcculloch, L. Pooley, M. D. Houslay, and G. Sweeney
Phosphodiesterase Isoforms in the Pulmonary Arterial Circulation of the Rat: Changes in Pulmonary Hypertension
J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 619 - 624.
[Abstract] [Full Text]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
H. Aly, R. Sahni, and J.-T. Wung
Weaning strategy with inhaled nitric oxide treatment in persistent pulmonary hypertension of the newborn
Arch. Dis. Child. Fetal Neonatal Ed., March 1, 1997; 76(2): 118F - 122.
[Abstract] [Full Text]

Home page
 Circ. Res.Home page
J. S. Lee, C. Adrie, H. J. Jacob, J. D. Roberts Jr, W. M. Zapol, and K. D. Bloch
Chronic Inhalation of Nitric Oxide Inhibits Neointimal Formation After Balloon-Induced Arterial Injury
Circ. Res., February 1, 1996; 78(2): 337 - 342.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online